CD4+ T cells in antitumor immunity: Utility of an Ii-Key HER2/neu hybrid peptide vaccine(AE37)

Expert Opinion on Biological Therapy

Volumn 9, Issue 1, 2009, Pages 71-78

  Mittendorf, Elizabeth A ^a   Holmes, Jarrod P ^b   Murray, James L ^a   Von Hofe, Eric ^c   Peoples, George E ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c Antigen Express Inc   (United States)

^d BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

AE37; Breast cancer; Ii Key; Peptide; Vaccine

Indexed keywords

AE37 PEPTIDE; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GP2 PEPTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE VACCINE; TRASTUZUMAB; UNCLASSIFIED DRUG; AE37 VACCINE; B LYMPHOCYTE ANTIGEN; HLA ANTIGEN CLASS 2;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; EX VIVO STUDY; EXPERIMENTAL MODEL; HUMAN; IMMUNOGENICITY; JOINT STIFFNESS; REVIEW; SKIN MANIFESTATION; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; ANIMAL; IMMUNOLOGY; INVARIANT CHAIN; NEOPLASM; PHASE 1 CLINICAL TRIAL; VACCINATION;

ANIMALIA;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS, PHASE I AS TOPIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; NEOPLASMS; RECEPTOR, ERBB-2; VACCINATION;

EID: 58149381639     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802614538     Document Type: Review

References (49)

1. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells. Immunol Today 1997;18(6):267-268 (Pubitemid 27261443)
2. Mittendorf EA, Holmes JP, Ponniah S, et al. The E75 HER2/neu. peptide vaccine. Cancer Immunol Immunother 2008;57(10):1511-1521
3. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997;18(4):175-182 (Pubitemid 27192179)
4. Van den Eynde B, Brichard VG. New tumor antigens recognized by T cells. Curr Opin Immunol 1995;7(5):674-681
5. Brossart P, Wirths S, Stuhler G, et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96(9):3102-3108 (Pubitemid 30815219)
6. Disis ML, Grabstein KH, Sleath PR, et al. Generation of immunity to the HER-2/neu. oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5(6):1289-1297 (Pubitemid 29282931)
7. Fisk B, Blevins TL, Wharton JT, et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181(6):2109-2117
8. Knutson KL, Schiffman K, Cheever MA, et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002;8(5):1014-1018 (Pubitemid 34517634)
9. Kono K, Takahashi A, Sugai H, et al. Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002;8(11):3394-3400 (Pubitemid 35340713)
10. Murray JL, Gillogly ME, Przepiorka D, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75(369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002;8(11):3407-3418
11. Peoples GE, Holmes JP, Hueman MT, et al. Combined clinical trial results of a HER2/neu(E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: US. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008;14(3):797-803 • A report on the largest preventive breast cancer trial published to date.
12. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer res 1998;58(21):4902-4908 (Pubitemid 28503688)
13. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20(11):2624-2632 (Pubitemid 34575634)
14. Holmes JP, Benavides LC, Gates JD, et al. Results of the first Phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008;26(20):3426-3433 •• This article reports on the results of the Phase I clinical trial that demonstrated the AE37 peptide to be safe and capable of generating an immune response.
15. Holmes JP, Gates JD, Benavides LC, et al. Optimal dose and schedule of a HER2/neu (E75) peptide vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2008;113(7):1666-1675
16. Knutson KL, Disis ML. Augmenting T helper cell immunity in cancer. Curr Drug Targets 2005;5(4):365-371 (Pubitemid 41722379)
17. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54(8):721-728 • A review of the role of T helper cells in cancer immunotherapy. (Pubitemid 40977140)
18. Xu M, Li J, Gulfo JV, et al. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J Immunol 2001;54(1-2):39-44 (Pubitemid 32592326)
19. Sotiriadou R, Perez SA, Gritzapis AD, et al. Peptide HER2 (776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 2001;85(10):1527-1534 (Pubitemid 34001585)
20. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998;188(12):2199-2204 (Pubitemid 29028492)
21. + T cell responses in antitumor immunity. Curr Opin Immunol 1998;10(5):588-594
22. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Nat Acad Sci USA 1993;90(8):3539-3543 (Pubitemid 23111402)
23. Levitsky HI, Lazenby A, Hayashi RJ, et al. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med 1994;179(4):1215-1224
24. + T cells in the antitumor immune response. J Exp Med 1998;188(12):2357-2368
25. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev 2006;6(5):383-393 •• An important review that highlights active immunotherapy for cancer and shows the importance of T helper cells.
26. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (New York) 2002;298(5594):850-854 (Pubitemid 35231542)
27. + T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 2004;64(5):1867-1874
28. Hillman GG, Kallinteris NL, Lu X, et al. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation. Cancer Treat Rev 2004;30(3):281-290
29. Altomonte M, Fonsatti E, Visintin A, et al. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? Oncogene 2003;22(42):6564-6569
30. Bertolino P, Trescol-Biemont MC, Thomas J, et al. Death by neglect as a deletional mechanism of peripheral tolerance. Int Immunol 1999;11(8):1225-1238 (Pubitemid 29355662)
31. Maldonado-Lopez R, Moser M. Dendritic cell subsets and the regulation of Th1/Th2 responses. Semin Immunol 2001;13(5):275-282 (Pubitemid 32744578)
32. Cheever MA, Chen W. Therapy with cultured T cells: principles revisited. Immunol Rev 1997;157:177-194 (Pubitemid 27303129)
33. Fruh K, Yang Y. Antigen presentation by MHC class I and its regulation by interferon γ Curr opin immunol 1999;11(1):76-81 (Pubitemid 29082341)
34. Tuttle TM, Anderson BW, Thompson WE, et al. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin Cancer Res 1998;4(8):2015-2024 (Pubitemid 28369189)
35. Disis ML, Cheever MA. HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol 1998;18(1-2):37-45 (Pubitemid 128670055)
36. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107(4):477-484 (Pubitemid 32167994)
37. Salazar LG, Fikes J, Southwood S, et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003;9(15):5559-5565 (Pubitemid 37499475)
38. Adams S, Albericio F, Alsina J, et al. Biological activity and therapeutic potential of homologs of an Ii peptide which regulates antigenic peptide binding to cell surface MHC class II molecules. Arzneimittel-Forschung 1997;47(9):1069-1077 (Pubitemid 27395667)
39. Adams S, Humphreys RE. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol 1995;25(6):1693-1702
40. Kallinteris NL, Lu X, Blackwell CE, et al. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Exp Opin Biol Ther 2006;6(12):1311-1321 • A comprehensive review of the Ii-Key technology. (Pubitemid 44875685)
41. Bertolino P, Rabourdin-Combe C. The MHC class II-associated invariant chain: a molecule with multiple roles in MHC class II biosynthesis and antigen presentation to CD4+ T cells. Crit Rev Immunol 1996;16(4):359-379 (Pubitemid 26419109)
42. Xu M, Jackson R, Adams S, et al. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1. Arzneimittel-Forschung 1999;49(9):791-799 (Pubitemid 29448520)
43. Gillogly ME, Kallinteris NL, Xu M, et al. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 2004;53(6):490-496 (Pubitemid 38680255)
44. Humphreys RE, Adams S, Koldzic G, et al. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 2000;18(24):2693-7 • An article demonstrating that linkage to the Ii-Key peptide results in increased antigen presentation that can increase potency to ≥ 250 times that of the unmodified class II epitope in vitro. (Pubitemid 30211577)
45. + T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain. Int J Cancer 2007;121(9):2031-2041
46. Benavides LC, Gates JC, Carmichael MG, et al. Response to a preventive HER2/neu peptide (E75) vaccine based on HER2/neu status. Proc American Association Cancer Res 2008;49:670
47. Jager E, Ringhoffer M, Dienes HP, et al. Granulocyte-macrophage-colony- stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996;67(1):54-62 (Pubitemid 26236069)
48. Mittendorf EA, Storrer CE, Foley RJ, et al. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 2006;106(11):2309-2317 (Pubitemid 43787653)
49. Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer 2007;110(8):1677-1686